Table 5

Predicted number of hospital and home IV antibiotic days in the next year for example patients

(A) Sets of patient characteristics A, B, C. All are aged 30 and female.
PredictorABC
FEV1%406080
FEV1% previous year406080
Body mass index202225
Pseudomonas aeruginosaYesYesNo
Staphylococcus aureusYesYesNo
Burkholderia cepaciaYesYesNo
CF-related diabetesYesYesNo
Hospital-IV-days, past year28140
Home-IV-days, past year28140
(B) Predicted number of hospital and home IV antibiotic days in the next year for nine example patients under no treatment effects, and imposing the effects of TEZ/IVA and ELEX/TEZ/IVA using approaches 1 and 2. Each set of characteristics A, B, C is considered in combination with each genotype category (1), (2), (3).
Genotype (1): F508del homoz (eligible for TEZ/IVA and ELEX/TEZ/IVA)Genotype (2): F508del heteroz+minimal (eligible for ELEX/TEZ/IVA)Genotype (3): Gating (eligible for IVA)
No treatment effects+TEZ/IVA*+ELEX/TEZ/IVA+
TEZ/IVA†
No treatment effects+TEZ/IVA*+ELEX/TEZ/IVA+
TEZ/IVA†
No treatment effects+TEZ/IVA* +ELEX/TEZ/IVA+
 TEZ/IVA†
Hospital-IV-days
Approach 1A34.231.825.334.625.628.6
B14.513.410.514.710.611.0
C1.81.61.21.81.21.2
Approach 2A34.222.212.734.612.828.6
B14.59.45.414.75.411.0
C1.81.20.71.80.71.2
Home-IV-days
Approach 1A25.224.121.124.020.118.1
B13.212.711.412.510.78.7
C5.25.14.74.94.43.2
Approach 2A25.216.49.324.08.918.1
B13.28.64.912.54.68.7
C5.23.41.94.91.83.2
  • Values of model predictors were chosen for nine example patients defined by three sets of patient characteristics (A, B, C), each combined with three different genotypes: (1) F508del homozygous (eligible for TEZ/IVA and ELEX/TEZ/IVA), (2) F508del heterozygous with a minimal function mutation (eligible for ELEX/TEZ/IVA only), (3) any gating mutation (assumed to be using ivacaftor, but not eligible for TEZ/IVA or ELEX/TEZ/IVA).

  • *With TEZ/IVA effect applied to eligible individuals.

  • †With ELEX/TEZ/IVA effect applied to eligible individuals, including those assumed to switch from TEZ/IVA.

  • ELEX, elexacaftor; IVA, ivacaftor; TEZ, tezacaftor.